Antagonistic antibodies targeting the inhibitory immune-checkpoint receptor PD-1 or its
ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve …

Carbohydrates—namely glycans—decorate every cell in the human body and most secreted
proteins. Advances in genomics, glycoproteomics and tools from chemical biology have …

Metabolic reprogramming is a hallmark of cancer. However, systematic characterizations of
metabolites in triple-negative breast cancer (TNBC) are still lacking. Our study profiled the …

Immune checkpoint blockade therapy has become a major weapon in fighting cancer.
Antibody drugs, such as anti-PD-1 and anti-PD-L1, demonstrate obvious advantages such …

Radiotherapy (RT) of colorectal cancer (CRC) can prime adaptive immunity against tumor-
associated antigen (TAA)–expressing CRC cells systemically. However, abscopal tumor …

The recent success of PD-1 and PD-L1 blockade in cancer therapy illustrates the important
role of the PD-1/PD-L1 pathway in the regulation of antitumor immune responses. However …

Lung cancer, of which non-small lung cancer is the most common subtype, represents the
leading cause of cancer related-death worldwide. It is now recognized that a significant …

Abstract N6-methyladenosine (m6A) has been reported as an important mechanism of
posttranscriptional regulation. Programmed death-ligand 1 (PD-L1) is a primary immune …

Immune checkpoint blockade targeting PD-1/PD-L1 has promising therapeutic efficacy in a
variety of tumors, but resistance during treatment is a major issue. In this review, we describe …

Immunotherapy with chimeric antigen receptor (CAR)–engineered T cells showed
exceptional successes in patients with refractory B cell malignancies. However, first-in …